SCHEMBL6718140

SCHEMBL6718140

C[CH]NC(C)CCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9306489 0.93 ADH1B (0.63)
SCHEMBL543188 0.84
SCHEMBL22157541 0.83 ADH1B (0.52)
SCHEMBL22157537 0.83 ADH1B (0.52)
SCHEMBL22157522 0.79 ADH1B (0.59)
SCHEMBL22157525 0.79 ADH1B (0.59)
SCHEMBL22617692 0.78
SCHEMBL269775 0.78
SCHEMBL22157510 0.78
SCHEMBL2964896 0.73 ALDH1A1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108641-A1 COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE ANTECIP BIOVENTURES II LLC 2024-04-04 US disclosed
US-11654152-B2 Compositions for oral administration of zoledronic acid or related compounds for treating disease ANTECIP BIOVENTURES II LLC (US) 2023-05-23 US disclosed
US-10463682-B2 Compositions for oral administration of zoledronic acid or related compounds for treating low back pain ANTECIP BIOVENTURES II LLC (US) 2019-11-05 US disclosed
US-20190314391-A1 COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE ANTECIP BIOVENTURES II LLC 2019-10-17 US disclosed
US-20190290664-A9 NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME ANTECIP BIOVENTURES II LLC 2019-09-26 US disclosed
US-10420782-B2 Dosage forms for oral administration of zoledronic acid or related compounds for treating disease ANTECIP BIOVENTURES II LLC (US) 2019-09-24 US disclosed
US-10413560-B2 Dosage forms for oral administration of zoledronic acid or related compounds for treating disease ANTECIP BIOVENTURES II LLC (US) 2019-09-17 US disclosed
US-10350227-B2 Neridronic acid for treating complex regional pain syndrome ANTECIP BIOVENTURES II LLC (US) 2019-07-16 US disclosed
US-10335424-B2 Compositions for oral administration of zoledronic acid or related compounds for treating disease ANTECIP BIOVENTURES II LLC (US) 2019-07-02 US disclosed
US-20190167703-A1 COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE ANTECIP BIOVENTURES II LLC 2019-06-06 US disclosed
WO-2015184003-A1 OSTEOCLAST INHIBITORS FOR PAIN ANTECIP BIOVENTURES II LLP (US) 2015-12-03 WO disclosed
US-20150157564-A1 METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS ANTECIP BIOVENTURES II LLC 2015-06-11 US disclosed
US-20150148312-A1 OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS ANTECIP BIOVENTURES II LLC 2015-05-28 US disclosed
US-20150141373-A1 Osteoclast Inhibitors for Knee Conditions ANTECIP BIOVENTURES II LLC 2015-05-21 US disclosed
US-20150141374-A1 Osteoclast Inhibitors for Knee Conditions ANTECIP BIOVENTURES II LLC 2015-05-21 US disclosed
US-20150133403-A1 Osteoclast Inhibitors for Knee Conditions ANTECIP BIOVENTURES II LLP 2015-05-14 US disclosed
US-20040097728-A1 Method for producing anellated tetrahydro-{1h}-triazoles BASF AKTIENGESELLSCHAFT (DE) 2004-05-20 US disclosed
US-6639070-B1 4-substituted 1,3,4-oxadiazines; herbicides BASF AKTIENGESELLSCHAFT (DE) 2003-10-28 US disclosed
EP-1187819-B1 N-SUBSTITUTED PERHYDRO DIAZINE BASF AG (DE) 2003-07-23 EP disclosed
US-6528455-B1 Post or preemergence herbicides such as 3-(4-chloro-2-fluoro -5-(1-methoxycarbonyl-1-vinyloxy)phenyl)-1-methyl-6-trifluoro methyl-2,4-pyrimidinedione BASF AKTIENGESELLSCHAFT (DE) 2003-03-04 US disclosed